Comparison 53. HA versus HA.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Pain in movement (number of patients improved)	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
1.1 1 to 4 weeks post‐injection	2	295	Risk Ratio (M‐H, Fixed, 95% CI)	0.89 [0.76, 1.03]
2 Pressure pain (number of patients improved)	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.1 1 to 4 weeks post‐injection	2	319	Risk Ratio (M‐H, Fixed, 95% CI)	0.94 [0.80, 1.10]
3 Lequesne Index (0‐24)	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
3.1 1 to 4 weeks post‐injection	1	233	Mean Difference (IV, Fixed, 95% CI)	0.46 [‐0.59, 1.51]
3.2 5 to 13 weeks post‐injection	2	261	Mean Difference (IV, Fixed, 95% CI)	0.29 [‐0.64, 1.23]
4 Patient global assessment	5		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
4.1 1 to 4 weeks post‐injection	3	358	Risk Ratio (M‐H, Fixed, 95% CI)	0.98 [0.84, 1.14]
4.2 5 to 13 weeks post‐injection	2	301	Risk Ratio (M‐H, Fixed, 95% CI)	0.91 [0.78, 1.05]
4.3 14 to 26 weeks post‐injection	1	49	Risk Ratio (M‐H, Fixed, 95% CI)	2.11 [0.67, 6.70]
4.4 45 to 52 weeks post‐injection	1	159	Risk Ratio (M‐H, Fixed, 95% CI)	0.85 [0.70, 1.03]